200 related articles for article (PubMed ID: 34871267)
1. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.
Al-Mashdali AF; Kashgary WR; Yassin MA
Medicine (Baltimore); 2021 Nov; 100(44):e27722. PubMed ID: 34871267
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
4. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract][Full Text] [Related]
5. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Zeeh FC; Meyer SC
Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
[TBL] [Abstract][Full Text] [Related]
6. Achievements and future outlook for JAK inhibitors in polycythaemia vera.
Cakmak I; Harrison C
Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
[TBL] [Abstract][Full Text] [Related]
8. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
Chang L; Duan MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
13. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
15. The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088
[TBL] [Abstract][Full Text] [Related]
16. How I treat polycythemia vera.
Passamonti F
Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
[TBL] [Abstract][Full Text] [Related]
17. Management of polycythemia vera: A survey of treatment patterns in Italy.
Palumbo GA; Breccia M; Baratè C; Bonifacio M; Elli EM; Iurlo A; Pugliese N; Rossi E; Guglielmelli P; Palandri F
Eur J Haematol; 2023 Feb; 110(2):161-167. PubMed ID: 36319575
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Tremblay D; Ronner L; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Mesa R; Yacoub A; Hoffman R; Moshier E; Zubizarreta N; Mascarenhas J
Leuk Res; 2021 Oct; 109():106629. PubMed ID: 34082375
[TBL] [Abstract][Full Text] [Related]
19. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
Kuykendall AT
Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
